Chinese vaccine CoronaVac efficacy: mild cases 78%, moderate and severe cases 100%
The vaccine has been announced to have a protective efficacy of 78% for mild cases and 100% for moderate to severe cases. The exact number of cases in the vaccine and placebo groups has not been announced, but it is promised that they will be in a scientific publication and an application for permission for emergency use in Brazil. It seems that the disagreements between the Brazilian and Chinese sides have not yet been completely eliminated as to whether to include one or two symptoms in the definition of a COVID-19 case (there is no disagreement about PCR-positiveness). In either case, the protective performance of CoronaVac is higher than the minimum requirement of the Brazilian regulator. Let me remind you that this vaccine has already been approved in Turkey, China and Bolivia.
CoronaVac has been approved for emergency use in Indonesia. To justify this decision, the Indonesian regulator referred to the results of an interim analysis of the protective efficacy of this vaccine in clinical trials in Indonesia – 65.3%. The number of COVID-19 cases for which protective efficacy was calculated is very small – 25. There is no additional information yet.Поділитися цим: